GSK Removes Blenrep From U.S. Market, Due Poor Clinical Trial Performance for Multiple Myeloma Drug
Blenrep failed to meet the goals of a confirmatory clinical trial required by the FDA to keep its accelerated approval license.
Blenrep failed to meet the goals of a confirmatory clinical trial required by the FDA to keep its accelerated approval license.